{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:02:58Z","timestamp":1787619778817,"version":"build-2736575974"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100016073","name":"Key Technologies Research and Development Program of Anhui Province","doi-asserted-by":"publisher","award":["1604a0802097"],"award-info":[{"award-number":["1604a0802097"]}],"id":[{"id":"10.13039\/100016073","id-type":"DOI","asserted-by":"publisher"}]},{"name":"China GuangHua Science and Technology Foundation","award":["KY20060212"],"award-info":[{"award-number":["KY20060212"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s13300-023-01520-3","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T09:02:06Z","timestamp":1704358926000},"page":"497-519","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Glycemic Control, Weight Management, Cardiovascular Safety, and Cost-Effectiveness of Semaglutide for Patients with Type 2 Diabetes Mellitus: A Rapid Review and Meta-analysis of Real-World Studies"],"prefix":"10.1007","volume":"15","author":[{"given":"Sihua","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3499-1944","authenticated-orcid":false,"given":"Jiajie","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"issue":"12","key":"1520_CR1","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925\u201366. https:\/\/doi.org\/10.1007\/s00125-022-05787-2.","journal-title":"Diabetologia"},{"key":"1520_CR2","doi-asserted-by":"publisher","unstructured":"Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014state-of-the-art. Mol Metab. 2021;46: 101102. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102.","DOI":"10.1016\/j.molmet.2020.101102"},{"issue":"11","key":"1520_CR3","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, et al. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763\u201374. https:\/\/doi.org\/10.1007\/s12325-018-0805-y.","journal-title":"Adv Ther"},{"issue":"2","key":"1520_CR4","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jval.2016.11.027","volume":"20","author":"R Cookson","year":"2017","unstructured":"Cookson R, Mirelman AJ, Griffin S, et al. Using cost-effectiveness analysis to address health equity concerns. Value Health. 2017;20(2):206\u201312. https:\/\/doi.org\/10.1016\/j.jval.2016.11.027.","journal-title":"Value Health"},{"key":"1520_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jclinepi.2020.10.007","volume":"130","author":"C Garritty","year":"2021","unstructured":"Garritty C, Gartlehner G, Nussbaumer-Streit B, et al. Cochrane rapid reviews methods group offers evidence-informed guidance to conduct rapid reviews. J Clin Epidemiol. 2021;130:13\u201322. https:\/\/doi.org\/10.1016\/j.jclinepi.2020.10.007.","journal-title":"J Clin Epidemiol"},{"key":"1520_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1520_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358: j4008. https:\/\/doi.org\/10.1136\/bmj.j4008.","journal-title":"BMJ"},{"issue":"1","key":"1520_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12916-021-02204-0","volume":"20","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med. 2022;20(1):23. https:\/\/doi.org\/10.1186\/s12916-021-02204-0.","journal-title":"BMC Med"},{"key":"1520_CR9","unstructured":"Viswanathan M, Ansari MT, Berkman ND, et al. Assessing the risk of bias of individual studies in systematic reviews of health care interventions. In: Agency for Healthcare Research and Quality, editor. Methods guide for effectiveness and comparative effectiveness reviews. Rockville, MD: Agency for Healthcare Research and Quality; 2012."},{"issue":"4","key":"1520_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. rating the quality of evidence\u2013study limitations (risk of bias). J Clin Epidemiol. 2011;64(4):407\u201315. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.07.017.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"1520_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153\u201360. https:\/\/doi.org\/10.1136\/ebmental-2019-300117.","journal-title":"Evid Based Ment Health"},{"issue":"7414","key":"1520_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"issue":"7109","key":"1520_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334. https:\/\/doi.org\/10.1136\/bmj.315.7109.629.","journal-title":"BMJ"},{"key":"1520_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2022.100944","volume":"28","author":"Y Alhindi","year":"2022","unstructured":"Alhindi Y, Avery A. The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: a systematic review and network meta-analysis. Contemp Clin Trials Commun. 2022;28: 100944. https:\/\/doi.org\/10.1016\/j.conctc.2022.100944.","journal-title":"Contemp Clin Trials Commun"},{"issue":"5","key":"1520_CR15","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1210\/clinem\/dgab905","volume":"107","author":"I Lingvay","year":"2022","unstructured":"Lingvay I, Bauer R, Baker-Knight J, et al. An indirect treatment comparison of semaglutide 2.0 mg vs dulaglutide 3.0 mg and 4.5 mg using multilevel network meta-regression. J Clin Endocrinol Metab. 2022;107(5):1461\u20139. https:\/\/doi.org\/10.1210\/clinem\/dgab905.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1520_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102511","volume":"16","author":"MS Zaazouee","year":"2022","unstructured":"Zaazouee MS, Hamdallah A, Helmy SK, et al. Semaglutide for the treatment of type 2 diabetes mellitus: a systematic review and network meta-analysis of safety and efficacy outcomes. Diabetes Metab Syndr. 2022;16(6): 102511. https:\/\/doi.org\/10.1016\/j.dsx.2022.102511.","journal-title":"Diabetes Metab Syndr"},{"issue":"5","key":"1520_CR17","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s13300-021-01034-w","volume":"12","author":"B Chubb","year":"2021","unstructured":"Chubb B, Gupta P, Gupta J, et al. Once-daily oral semaglutide versus injectable GLP-1 RAs in people with type 2 diabetes inadequately controlled on basal insulin: Systematic review and network meta-analysis. Diabetes Ther. 2021;12(5):1325\u201339. https:\/\/doi.org\/10.1007\/s13300-021-01034-w.","journal-title":"Diabetes Ther"},{"issue":"30","key":"1520_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026431","volume":"100","author":"X-Y Duan","year":"2021","unstructured":"Duan X-Y, Liu S-Y, Yin D-G. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients. Medicine (Baltimore). 2021;100(30): e26431. https:\/\/doi.org\/10.1097\/MD.0000000000026431.","journal-title":"Medicine (Baltimore)"},{"key":"1520_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108656","volume":"172","author":"J Li","year":"2021","unstructured":"Li J, He K, Ge J, et al. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2021;172: 108656. https:\/\/doi.org\/10.1016\/j.diabres.2021.108656.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"1520_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/fjc.0000000000000916","volume":"77","author":"M Qiu","year":"2021","unstructured":"Qiu M, Ding LL, Wei XB, et al. Comparative efficacy of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular events in type 2 diabetes: a network meta-analysis. J Cardiovasc Pharmacol. 2021;77(1):34\u20137. https:\/\/doi.org\/10.1097\/fjc.0000000000000916.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"9","key":"1520_CR21","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1111\/dom.14451","volume":"23","author":"A Tsapas","year":"2021","unstructured":"Tsapas A, Karagiannis T, Kakotrichi P, et al. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab. 2021;23(9):2116\u201324. https:\/\/doi.org\/10.1111\/dom.14451.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1520_CR22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.pcd.2020.08.017","volume":"15","author":"XB Wei","year":"2021","unstructured":"Wei XB, Wei W, Ding LL, et al. Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: a network meta-analysis of large randomized trials. Prim Care Diabetes. 2021;15(2):208\u201311. https:\/\/doi.org\/10.1016\/j.pcd.2020.08.017.","journal-title":"Prim Care Diabetes"},{"key":"1520_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.695182","volume":"12","author":"P Zhong","year":"2021","unstructured":"Zhong P, Zeng H, Huang M, et al. Efficacy and safety of subcutaneous and oral semaglutide administration in patients with type 2 diabetes: a meta-analysis. Front Pharmacol. 2021;12: 695182. https:\/\/doi.org\/10.3389\/fphar.2021.695182.","journal-title":"Front Pharmacol"},{"key":"1520_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.759262","volume":"12","author":"C Zhuo","year":"2021","unstructured":"Zhuo C, Lin C, Zhou C, et al. Comparative cardio-renal outcomes of type 2 diabetes patients administered glucagon-like peptide-1 receptor agonists: a network meta-analysis. Front Pharmacol. 2021;12: 759262. https:\/\/doi.org\/10.3389\/fphar.2021.759262.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1520_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12933-020-01070-z","volume":"19","author":"OM Alfayez","year":"2020","unstructured":"Alfayez OM, Almohammed OA, Alkhezi OS, et al. Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis. Cardiovasc Diabetol. 2020;19(1):96. https:\/\/doi.org\/10.1186\/s12933-020-01070-z.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"1520_CR26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/dom.13899","volume":"22","author":"I Avgerinos","year":"2020","unstructured":"Avgerinos I, Michailidis T, Liakos A, et al. Oral semaglutide for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2020;22(3):335\u201345. https:\/\/doi.org\/10.1111\/dom.13899.","journal-title":"Diabetes Obes Metab"},{"issue":"Supplement 1","key":"1520_CR27","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1016\/j.jval.2020.04.198","volume":"23","author":"KT Fazioli","year":"2020","unstructured":"Fazioli KT, Borrelli E, Bradt P, et al. PDB9 The comparative efficacy of oral semaglutide for the treatment of type 2 diabetes mellitus (T2DM): a systematic review and network meta-analysis (NMA). Value Health. 2020;23(Supplement 1):S109. https:\/\/doi.org\/10.1016\/j.jval.2020.04.198.","journal-title":"Value Health"},{"issue":"7","key":"1520_CR28","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/dom.14008","volume":"22","author":"H Hussein","year":"2020","unstructured":"Hussein H, Zaccardi F, Khunti K, et al. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis. Diabetes Obes Metab. 2020;22(7):1035\u201346. https:\/\/doi.org\/10.1111\/dom.14008.","journal-title":"Diabetes Obes Metab"},{"issue":"Supplement 1","key":"1520_CR29","doi-asserted-by":"publisher","first-page":"S257","DOI":"10.1007\/s00125-020-05221-5","volume":"63","author":"P Kakotrichi","year":"2020","unstructured":"Kakotrichi P, Karagiannis T, Avgerinos I, et al. Comparative effects of medications for type 2 diabetes on body weight: a systematic review and network meta-analysis of 394 trials. Diabetologia. 2020;63(Supplement 1):S257. https:\/\/doi.org\/10.1007\/s00125-020-05221-5.","journal-title":"Diabetologia"},{"issue":"4","key":"1520_CR30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.7326\/M20-0864","volume":"173","author":"A Tsapas","year":"2020","unstructured":"Tsapas A, Avgerinos I, Karagiannis T, et al. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med. 2020;173(4):278\u201386. https:\/\/doi.org\/10.7326\/M20-0864.","journal-title":"Ann Intern Med"},{"issue":"6","key":"1520_CR31","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1007\/s13300-019-00706-y","volume":"10","author":"S Nuhoho","year":"2019","unstructured":"Nuhoho S, Gupta J, Hansen BB, et al. Orally administered semaglutide versus glp-1 ras in patients with type 2 diabetes previously receiving 1\u20132 oral antidiabetics: Systematic review and network meta-analysis. Diabetes Ther. 2019;10(6):2183\u201399. https:\/\/doi.org\/10.1007\/s13300-019-00706-y.","journal-title":"Diabetes Ther"},{"key":"1520_CR32","doi-asserted-by":"publisher","unstructured":"Shi FH, Li H, Cui M, et al. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2018;9:576. https:\/\/doi.org\/10.3389\/fphar.2018.00576.","DOI":"10.3389\/fphar.2018.00576"},{"issue":"3","key":"1520_CR33","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s13300-018-0397-1","volume":"9","author":"N Webb","year":"2018","unstructured":"Webb N, Orme M, Witkowski M, et al. A network meta-analysis comparing semaglutide once-weekly with other GLP-1 receptor agonists in Japanese patients with type 2 diabetes. Diabetes Ther. 2018;9(3):973\u201386. https:\/\/doi.org\/10.1007\/s13300-018-0397-1.","journal-title":"Diabetes Ther"},{"issue":"3","key":"1520_CR34","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s13300-018-0428-y","volume":"9","author":"M Witkowski","year":"2018","unstructured":"Witkowski M, Wilkinson L, Webb N, et al. A systematic literature review and network meta-analysis comparing once-weekly semaglutide with other GLP-1 receptor agonists in patients with type 2 diabetes previously receiving basal insulin. Diabetes Ther. 2018;9(3):1233\u201351. https:\/\/doi.org\/10.1007\/s13300-018-0428-y.","journal-title":"Diabetes Ther"},{"issue":"3","key":"1520_CR35","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s13300-018-0424-2","volume":"9","author":"M Witkowski","year":"2018","unstructured":"Witkowski M, Wilkinson L, Webb N, et al. A systematic literature review and network meta-analysis comparing once-weekly semaglutide with other GLP-1 receptor agonists in patients with type 2 diabetes previously receiving 1\u20132 oral anti-diabetic drugs. Diabetes Ther. 2018;9(3):1149\u201367. https:\/\/doi.org\/10.1007\/s13300-018-0424-2.","journal-title":"Diabetes Ther"},{"issue":"4","key":"1520_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1055\/a-2007-2061","volume":"131","author":"M Menzen","year":"2023","unstructured":"Menzen M, Landsvig Berentzen T, Catarig A-M, et al. Real-world use of once-weekly semaglutide in type 2 diabetes: results from SURE Germany. Exp Clin Endocrinol Diabetes. 2023;131(4):205\u201315. https:\/\/doi.org\/10.1055\/a-2007-2061.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"7","key":"1520_CR37","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1111\/dom.15045","volume":"25","author":"K Mohammedi","year":"2023","unstructured":"Mohammedi K, Belhatem N, Berentzen TL, et al. Once-weekly semaglutide use in patients with type 2 diabetes: results from the SURE France multicentre, prospective, observational study. Diabetes Obes Metab. 2023;25(7):1855\u201364. https:\/\/doi.org\/10.1111\/dom.15045.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1520_CR38","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1111\/dom.15020","volume":"25","author":"R Napoli","year":"2023","unstructured":"Napoli R, Berra C, Catarig AM, et al. Once-weekly semaglutide use in patients with type 2 diabetes: real-world data from the SURE Italy observational study. Diabetes Obes Metab. 2023;25(6):1658\u201367. https:\/\/doi.org\/10.1111\/dom.15020.","journal-title":"Diabetes Obes Metab"},{"issue":"17","key":"1520_CR39","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.3390\/jcm11174938","volume":"11","author":"V Bellido","year":"2022","unstructured":"Bellido V, Abreu Pad\u00edn C, Catarig A-M, et al. Once-weekly semaglutide use in patients with type 2 diabetes: results from the SURE Spain multicentre, prospective, observational study. J Clin Med. 2022;11(17):4938. https:\/\/doi.org\/10.3390\/jcm11174938.","journal-title":"J Clin Med"},{"issue":"12","key":"1520_CR40","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.3390\/nu14122414","volume":"14","author":"S Volpe","year":"2022","unstructured":"Volpe S, Lisco G, Racaniello D, et al. Once-weekly semaglutide induces an early improvement in body composition in patients with type 2 diabetes: A 26-week prospective real-life study. Nutrients. 2022;14(12):2414. https:\/\/doi.org\/10.3390\/nu14122414.","journal-title":"Nutrients"},{"issue":"3","key":"1520_CR41","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s12325-022-02385-x","volume":"40","author":"BHR Wolffenbuttel","year":"2023","unstructured":"Wolffenbuttel BHR, Brugts MP, Catarig AM, et al. Once-weekly semaglutide use in type 2 diabetes: real-world data from the SURE Netherlands observational study. Adv Ther. 2023;40(3):920\u201333. https:\/\/doi.org\/10.1007\/s12325-022-02385-x.","journal-title":"Adv Ther"},{"issue":"11","key":"1520_CR42","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1007\/s13300-021-01141-8","volume":"12","author":"P Holmes","year":"2021","unstructured":"Holmes P, Bell HE, Bozkurt K, et al. Real-world use of once-weekly semaglutide in type 2 diabetes: results from the sure UK multicentre, prospective. Obs Study Diabetes Ther. 2021;12(11):2891\u2013905. https:\/\/doi.org\/10.1007\/s13300-021-01141-8.","journal-title":"Obs Study Diabetes Ther"},{"issue":"5","key":"1520_CR43","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.pcd.2021.06.008","volume":"15","author":"N Rajamand Ekberg","year":"2021","unstructured":"Rajamand Ekberg N, Bodholdt U, Catarig AM, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark\/Sweden multicentre, prospective, observational study. Prim Care Diabetes. 2021;15(5):871\u20138. https:\/\/doi.org\/10.1016\/j.pcd.2021.06.008.","journal-title":"Prim Care Diabetes"},{"key":"1520_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108931","volume":"178","author":"G Rudofsky","year":"2021","unstructured":"Rudofsky G, Catarig AM, Favre L, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study. Diabetes Res Clin Pr. 2021;178: 108931. https:\/\/doi.org\/10.1016\/j.diabres.2021.108931.","journal-title":"Diabetes Res Clin Pr"},{"issue":"10","key":"1520_CR45","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1111\/dom.14468","volume":"23","author":"JF Yale","year":"2021","unstructured":"Yale JF, Catarig AM, Grau K, et al. Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study. Diabetes Obes Metab. 2021;23(10):2269\u201378. https:\/\/doi.org\/10.1111\/dom.14468.","journal-title":"Diabetes Obes Metab"},{"key":"1520_CR46","doi-asserted-by":"publisher","unstructured":"Ruan Z, Yang L, Shi H, et al. The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 diabetes: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2021;21(2):221\u201333. https:\/\/doi.org\/10.1080\/14737167.2021.1860022.","DOI":"10.1080\/14737167.2021.1860022"},{"issue":"1","key":"1520_CR47","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13098-021-00705-9","volume":"13","author":"C Eberle","year":"2021","unstructured":"Eberle C, Stichling S. Impact of COVID-19 lockdown on glycemic control in patients with type 1 and type 2 diabetes mellitus: a systematic review. Diabetol Metab Syndr. 2021;13(1):95. https:\/\/doi.org\/10.1186\/s13098-021-00705-9.","journal-title":"Diabetol Metab Syndr"},{"key":"1520_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.892702","volume":"13","author":"G Di Dalmazi","year":"2022","unstructured":"Di Dalmazi G, Coluzzi S, Baldassarre M, et al. Effectiveness and tolerability of once-weekly GLP-1 receptor agonists in clinical practice: a focus on switching between once-weekly molecules in type 2 diabetes. Front Endocrinol (Lausanne). 2022;13: 892702. https:\/\/doi.org\/10.3389\/fendo.2022.892702.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"1520_CR49","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1007\/s12325-022-02196-0","volume":"39","author":"I Romera","year":"2022","unstructured":"Romera I, Artime E, Ihle K, et al. A retrospective observational study examining the generalizability of glucagon-like peptide 1 receptor agonist cardiovascular outcome trials to the real-world population with type 2 diabetes in Spain: the Represent study. Adv Ther. 2022;39(8):3589\u2013601. https:\/\/doi.org\/10.1007\/s12325-022-02196-0.","journal-title":"Adv Ther"},{"issue":"10","key":"1520_CR50","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1007\/s13300-020-00908-9","volume":"11","author":"KS Boye","year":"2020","unstructured":"Boye KS, Sapin H, Garc\u00eda-P\u00e9rez L-E, et al. The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): baseline patient-reported outcomes. Diabetes Ther Res Treat Educ Diabetes Relat Disord. 2020;11(10):2383\u201399. https:\/\/doi.org\/10.1007\/s13300-020-00908-9.","journal-title":"Diabetes Ther Res Treat Educ Diabetes Relat Disord"},{"issue":"2","key":"1520_CR51","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/dom.14580","volume":"24","author":"J Webb","year":"2022","unstructured":"Webb J, Mount J, von Arx LB, et al. Cardiovascular risk profiles: a cross-sectional study evaluating the generalizability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN-6 to the real-world type 2 diabetes population in the United Kingdom. Diabetes Obes Metab. 2022;24(2):289\u201395. https:\/\/doi.org\/10.1111\/dom.14580.","journal-title":"Diabetes Obes Metab"},{"key":"1520_CR52","doi-asserted-by":"publisher","unstructured":"Cai X, Ji L. Generalizability of the results of cardiovascular outcome trials of glucagon-like peptide 1 receptor agonists in Chinese patients with type 2 diabetes mellitus. Diabetes Ther. 2021;12(7):1861\u201370. https:\/\/doi.org\/10.1007\/s13300-021-01079-x.","DOI":"10.1007\/s13300-021-01079-x"},{"key":"1520_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.109824","volume":"186","author":"S Ghosal","year":"2022","unstructured":"Ghosal S, Sinha B. The cardiovascular benefits of GLP1-RAs are related to their positive effect on glycemic control: a meta-regression analysis. Diabetes Res Clin Pr. 2022;186: 109824. https:\/\/doi.org\/10.1016\/j.diabres.2022.109824.","journal-title":"Diabetes Res Clin Pr"},{"key":"1520_CR54","doi-asserted-by":"publisher","unstructured":"Bandyopadhyay I, Dave S, Rai A, et al. Oral semaglutide in the management of type 2 DM: clinical status and comparative analysis. Curr Drug Targets. 2022;23(3):311\u201327. https:\/\/doi.org\/10.2174\/1389450122666210901125420.","DOI":"10.2174\/1389450122666210901125420"},{"issue":"12","key":"1520_CR55","doi-asserted-by":"publisher","first-page":"8208","DOI":"10.1021\/acs.jmedchem.1c01856","volume":"65","author":"DA Griffith","year":"2022","unstructured":"Griffith DA, Edmonds DJ, Fortin JP, et al. A small-molecule oral agonist of the human glucagon-like peptide-1 receptor. J Med Chem. 2022;65(12):8208\u201326. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01856.","journal-title":"J Med Chem"},{"key":"1520_CR56","doi-asserted-by":"publisher","unstructured":"Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol (Lausanne). 2021;12:786732. https:\/\/doi.org\/10.3389\/fendo.2021.645563.","DOI":"10.3389\/fendo.2021.645563"},{"key":"1520_CR57","doi-asserted-by":"publisher","first-page":"1149328","DOI":"10.3389\/fendo.2023.1149328","volume":"14","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Zhang Q, Tan Y, et al. GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis. Front Endocrinol (Lausanne). 2023;14:1149328. https:\/\/doi.org\/10.3389\/fendo.2023.1149328.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1520_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.998816","volume":"13","author":"R Guan","year":"2022","unstructured":"Guan R, Yang Q, Yang X, et al. Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: a bayesian network meta-analysis. Front Pharmacol. 2022;13: 998816. https:\/\/doi.org\/10.3389\/fphar.2022.998816.","journal-title":"Front Pharmacol"},{"key":"1520_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.920541","volume":"13","author":"G Lisco","year":"2022","unstructured":"Lisco G, De Tullio A, Disoteo O, et al. Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis. Front Endocrinol (Lausanne). 2022;13: 920541. https:\/\/doi.org\/10.3389\/fendo.2022.920541.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"1520_CR60","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","volume":"65","author":"T Karagiannis","year":"2022","unstructured":"Karagiannis T, Avgerinos I, Liakos A, et al. Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022;65(8):1251\u201361. https:\/\/doi.org\/10.1007\/s00125-022-05715-4.","journal-title":"Diabetologia"},{"issue":"5","key":"1520_CR61","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/dom.14979","volume":"25","author":"WJ Valentine","year":"2023","unstructured":"Valentine WJ, Hoog M, Mody R, et al. Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States. Diabetes Obes Metab. 2023;25(5):1292\u2013300. https:\/\/doi.org\/10.1111\/dom.14979.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1520_CR62","doi-asserted-by":"publisher","first-page":"276","DOI":"10.18553\/jmcp.2023.29.3.276","volume":"29","author":"X Zhang","year":"2023","unstructured":"Zhang X, McAdam MC. Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States. J Manag Care Spec Pharm. 2023;29(3):276\u201384. https:\/\/doi.org\/10.18553\/jmcp.2023.29.3.276.","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-023-01520-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-023-01520-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-023-01520-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T00:27:30Z","timestamp":1707006450000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-023-01520-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1520"],"URL":"https:\/\/doi.org\/10.1007\/s13300-023-01520-3","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]},"assertion":[{"value":"9 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Si-Hua Wang, Sheng Wang, Yan Wang and Jia-Jie Luan declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}